Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.
about
Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibodySevere murine lung immunopathology elicited by the pathogenic equine herpesvirus 1 strain RacL11 correlates with early production of macrophage inflammatory proteins 1alpha, 1beta, and 2 and tumor necrosis factor alphaAbsence of macrophage inflammatory protein-1alpha prevents the development of blinding herpes stromal keratitisPathogenesis of herpes simplex virus type 1-induced corneal inflammation in perforin-deficient mice.Localization of a passively transferred human recombinant monoclonal antibody to herpes simplex virus glycoprotein D to infected nerve fibers and sensory neurons in vivo.Herpes simplex virus and the chemokines that mediate the inflammation.Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.Dose-dependent activation of lymphocytes in endotoxin-induced airway inflammation.Herpes keratitis.Corneal lymphangiogenesis in herpetic stromal keratitisModulation of polymorphonuclear cell interleukin-8 secretion by human monoclonal antibodies to type 8 pneumococcal capsular polysaccharideA Functional Type I Interferon Pathway Drives Resistance to Cornea Herpes Simplex Virus Type 1 Infection by Recruitment of LeukocytesResident Corneal Cells Communicate with Neutrophils Leading to the Production of IP-10 during the Primary Inflammatory Response to HSV-1 Infection.New concepts in antibody-mediated immunity.Recurrent herpetic stromal keratitis in mice: a model for studying human HSK.Therapeutic Strategy for the Prevention of Pseudorabies Virus Infection in C57BL/6 Mice by 3D8 scFv with Intrinsic Nuclease Activity.Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in miceHerpesvirus entry mediator on radiation-resistant cell lineages promotes ocular herpes simplex virus 1 pathogenesis in an entry-independent manner.CXCL1-deficient mice are highly sensitive to pseudomonas aeruginosa but not herpes simplex virus type 1 corneal infectionEffect of anti-CXCL10 monoclonal antibody on herpes simplex virus type 1 keratitis and retinal infection.An increase in herpes simplex virus type 1 in the anterior segment of the eye is linked to a deficiency in NK cell infiltration in mice deficient in CXCR3Murine Corneal Inflammation and Nerve Damage After Infection With HSV-1 Are Promoted by HVEM and Ameliorated by Immune-Modifying Nanoparticle Therapy.Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation.Understanding the Role of Chemokines and Cytokines in Experimental Models of Herpes Simplex Keratitis.Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and ProtectVirus-cell interactions regulating induction of tumor necrosis factor alpha production in macrophages infected with herpes simplex virus.Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.Infection of murine keratinocytes with herpes simplex virus type 1 induces the expression of interleukin-10, but not interleukin-1 alpha or tumour necrosis factor-alpha.Consequences of CXCL10 and IL-6 induction by the murine IFN-alpha1 transgene in ocular herpes simplex virus type 1 infectionAbnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1.Penetration of engineered antibody fragments into the eye.Effect of undernourishment on Herpes Simplex Virus Type 1 ocular infection in the Wistar rat model.
P2860
Q28543018-58A46086-A833-4575-B814-0F29B727FEACQ33603498-3E566122-E4C0-4B2F-BCDE-FE4738FA8CBAQ33782634-89D73825-C025-47AB-B3D3-0BEF0509061AQ33812978-C98226DB-45FD-4301-826F-E99615086097Q33821358-4DDFF529-AD99-4FB5-BE55-725DB52CD6A6Q33825406-020E6D05-B077-4CE2-9991-A63591349B59Q33870528-C1FE584C-14F6-4F18-A258-E52E2A534C53Q34005287-F13F18F3-95B6-4226-BDBA-DD10838E71D2Q34297293-67C67ED5-7DB0-431E-ABB9-ADC6D6C51CE8Q34674612-1C97A1CD-E2DA-4682-8A77-785D36224653Q34940688-5E977221-2477-4799-94C4-1341AA2C66B9Q35058178-2BDEF471-685E-4F25-AEAF-C4ABF72C1F59Q35864871-9D2FBEEB-879E-4BE7-905E-144C8449A82CQ35926507-A719E0D6-E377-4DB4-B020-2E800368A500Q35944884-95154C57-A771-4EC5-A098-646CD97EAB0EQ36107251-F4E07FBA-41EC-4E72-A7D8-C461433AFC76Q36171987-88A7DE4A-D7F1-4A9F-B246-8B80F9408DB2Q36205873-8E79908A-90BC-497C-872B-631DE13E85BEQ36292644-545A055B-26FA-41A1-930C-BB3BF72BB283Q36464696-4A6AF30D-5C5D-4BD7-839F-6E43C05B8A4BQ36677447-006E2183-62D0-4854-A816-B0BCA6A6CE0AQ37600490-ED9F0A45-F4C3-4515-A786-DA1134AFEE9EQ37691860-A4C79218-8554-4520-A337-780F6471B5E5Q38685413-438809A3-4C4E-4710-B3AD-2EE10F13E869Q39574405-F2828917-1429-465C-BA51-00D8603F869FQ39604619-627FF608-75A7-4CEC-A695-52B161B9DD0AQ39654344-3DA28631-037C-43B0-A7A0-2DC8826EEBF0Q40744097-01B02B6D-EE12-413D-BC5F-650F1E2EB9D9Q40798416-CAD6DE4E-9A09-408E-8F7B-F9DA6030D0C2Q41814635-84EA9374-CB98-4EF8-AD09-769A9209C904Q43975336-A1F6866C-7334-4A5E-8814-CA0E7E3C3A2EQ45731989-AA55BE13-B92C-4AD1-882A-5D4DD9D342F0
P2860
Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Protective antibody therapy is ...... irus type 1 corneal infection.
@ast
Protective antibody therapy is ...... irus type 1 corneal infection.
@en
type
label
Protective antibody therapy is ...... irus type 1 corneal infection.
@ast
Protective antibody therapy is ...... irus type 1 corneal infection.
@en
prefLabel
Protective antibody therapy is ...... irus type 1 corneal infection.
@ast
Protective antibody therapy is ...... irus type 1 corneal infection.
@en
P2093
P2860
P1433
P1476
Protective antibody therapy is ...... virus type 1 corneal infection
@en
P2093
P2860
P304
P407
P577
1996-02-01T00:00:00Z